PASylation® technology comprises the conjugation–via genetic fusion or chemical coupling–
of pharmacologically active compounds, such as proteins, peptides and low molecular
weight drugs, with natively disordered biosynthetic polymers made of the small L-amino
acids Pro, Ala and/or Ser. Such proline/alanine-rich sequences (PAS) are highly soluble in
physiological solution and stably adopt random coil conformation, which results in an
expanded hydrodynamic volume. Consequently, PAS-drug conjugates show retarded …